Bruker event mit M2AIND: MALDI Innovations in Pharma
Februar 21 - Februar 22
Building on 25 years of excellence in MALDI mass spectrometry, Bruker has developed a new set of technologies that are impacting the pharmacological related industry far beyond the traditional role of quantitation and process monitoring. From lead generation all the way through to pre-clinical assessment, drug companies are employing these advanced MALDI based technologies in a wide range of roles to increase the speed and specificity of hit finding, ADME/tox and PK/PD studies, drug-to-target validation studies, and much more. Come join several industry leaders from top pharma around the globe as they present their perspectives on using these advances to streamline the drug development process.
Please Register here